Peter Rademacher, PhD

Peter Rademacher, PhD

Associate Director, DMPK

Peter Rademacher, PhD

Associate Director, DMPK

Peter joined DiCE Molecules in 2020 and leads the DMPK team. Before DiCE, Peter was a scientist at Global Blood Therapeutics where he made significant contributions to the NDA filing for Oxybryta, which was approved in November 2019. In addition, Peter served as a subject matter expert for drug-drug interactions and metabolite identification as well as a DMPK project representative for several pipeline projects.

Peter completed his post-doctoral work at Lawrence Berkeley National Labs and obtained his PhD from the University of Washington.

Management Team
Board of Directors